HighTide Therapeutics, Inc. Reports Preclinical HTD1801 Data Reducing Cyst Burden in ADPKD ModelTradingView·Oct 23, 2026 at 01:53 AM02511-0.37%
ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney DiseaseAsian Corporate Newswire·Oct 23, 2026 at 01:53 AM02511-0.37%
Hong Kong's Forgotten Small Caps Are Splitting in TwoGlobal Report·Oct 13, 2026 at 10:51 AM00165+0.11%03996+0.56%
Hong Kong's Niche Leaders Pivot: Pet Care, AI Security Drive Turnaround PlaysGlobal Report·Oct 13, 2026 at 09:23 AM06601-0.79%004930.00%
Hong Kong's Second Row Is Running a Survival TestGlobal Report·Oct 6, 2026 at 10:49 AM01286+0.11%02128-0.18%
Legacy Models Crumble as Hong Kong Small-Caps Pivot to SurvivalGlobal Report·Oct 6, 2026 at 09:16 AM06228-2.18%068080.00%
Property Stimulus Lifted Two of Hong Kong's Long-Tail Names. Guoquan Kept Falling.Global Report·Sep 29, 2026 at 10:51 AM01003-3.00%09663+20.83%
Weekly Recap | HIGHTIDE-B +6.01%, outperforming the Hang Seng IndexWeekly Review·Sep 12, 2026 at 05:38 AM02511-0.37%
Inside the Fringes of HKEX: HighTide's Earnings and Everest's MomentumGlobal Report·Sep 8, 2026 at 11:33 AM02511-0.37%099590.00%
HighTide Therapeutics Grants Performance-Linked Share Options and AwardsTip Ranks·Sep 1, 2026 at 02:14 PM02511-0.37%
HighTide FY26 H1 net loss widens 46.9% to RMB 167.27 millionPUBT·Aug 31, 2026 at 01:23 PM02511-0.37%APO-0.06%